logo
ProjectEnded

A rapid, low-cost, cervical cancer screening platform

One of 5,497 projects Taiyo tracks in Belgium.

Source: EU Funding & Tenders Portal

Cervical cancer causes 13.000 deaths and 34.000 new cases in the European Union. 200M tests are performed worldwide per year representing a $3,4B market. Today two tests are performed to diagnose cervical cancer. Firstly, a cervical smear is analysed by a pathologist via a visual subjective inspection using traditional microscopy. This is an 8-step process performed by several persons at different

Status
Closed
Location
Belgium
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about A rapid, low-cost, cervical cancer screening platform

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “A rapid, low-cost, cervical cancer screening platform” is an infrastructure initiative, located in Belgium. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Cervical cancer causes 13.000 deaths and 34.000 new cases in the European Union. 200M tests are performed worldwide per year representing a $3,4B market. Today two tests are performed to diagnose cervical cancer. Firstly, a cervical smear is analysed by a pathologist via a visual subjective inspection using traditional microscopy. This is an 8-step process performed by several persons at different locations. Secondly, if positive, a molecular 4-step HPV test is performed. Results are available after 3 to 4 weeks causing anxiety and frustration for the patient. Typical instruments are expensive and have high related operational costs. Ovizio has designed a direct read vial allowing for the sample to be directly analysed without manipulation. The technology automatically generates objective data, identifying cells, detecting malicious cells and combines cytology and HPV in one test. This is a 3-step process: 1. sampling, 2. analysing, 3. report generation. The test is performed on a small low-cost device giving results in minutes rather than days allowing for near patient testing. A proof of concept and alpha prototype have been built with basic software algorithms. Several test have been performed at hospitals in Belgium and France resulting in two scientific publications and enthusiasm from key opinion leaders. The breakthrough technology transforms microscopic images into actionable data, corresponding to a market need of faster and improved testing, allowing healthcare organisations of member states to reduce costs and improve testing ratio’s. The company has a team that has done it before completed with highly skilled subject experts in the field and has launched 3 products laying the foundations for this project.

Location

Country

Belgium

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Article published date

2026-01-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project